Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy

Mostafa Yazdimamaghani ^{a b}, Oleg V. Kolupaev ^{a c}, Chaemin Lim ^{b d}, Duhyeong Hwang ^{b e}, Sonia J. Laurie ^a, Charles M. Perou ^a, Alexander V. Kabanov ^{a b}, Jonathan S. Serody ^{a f g}

I’m thrilled to share our latest #Biomaterials paper! We present a new approach that combines radiotherapy with nanoformulated #TLR7/8 agonist and #PI3Kdelta inhibitor to eradicate triple-negative breast cancer tumors. Our work presented in this paper highlights immunomodulatory agents' role in improving radiotherapy's therapeutic benefits. It explains the importance of identifying target immune cell subsets for efficient immunosuppressive tumor microenvironment reprogramming as a promising therapeutic approach for treating immunosuppressed breast tumors.

Read more : Sciencedirct.com